BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alves Do Rego C, Collongues N. Neuromyelitis optica spectrum disorders: Features of aquaporin-4, myelin oligodendrocyte glycoprotein and double-seronegative-mediated subtypes. Rev Neurol (Paris) 2018;174:458-70. [PMID: 29685427 DOI: 10.1016/j.neurol.2018.02.084] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Antonescu Ghelmez D, Moraru A, Antonescu F, Chelmambet AS, Bucur AI, Tuţǎ S. Double seropositive neuromyelitis optica associated with COVID-19: A case report. Front Neurol 2022;13:1004132. [DOI: 10.3389/fneur.2022.1004132] [Reference Citation Analysis]
2 Ong Z, Arip M, Ching Y, Kumar L, Terumalay S, Sim S, Adenan S, Viswanathan S. The Prevalence, Demographics, Clinical Features, Neuroimaging, and Interethnic Differences of MOG Disease in Malaysia with Global Perspectives. Multiple Sclerosis and Related Disorders 2022. [DOI: 10.1016/j.msard.2022.104168] [Reference Citation Analysis]
3 Chaara T, Gilardin L, Nielly H, Le Burel S, Bousquet A, Beaucreux C, Kearns K, Salvadori A, Piljan M, Sollier M, Mayaux J, Rohaut B, Le Guennec L, Vanquaethem H, Michon A. Le croiseur était coulé. La Revue de Médecine Interne 2022. [DOI: 10.1016/j.revmed.2022.04.015] [Reference Citation Analysis]
4 El Khoury Y, Gebelin M, de Sèze J, Patte-Mensah C, Marcou G, Varnek A, Mensah-Nyagan AG, Hellwig P, Collongues N. Rapid Discrimination of Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Using Machine Learning on Infrared Spectra of Sera. Int J Mol Sci 2022;23:2791. [PMID: 35269934 DOI: 10.3390/ijms23052791] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Pandit L, Malli C, D'Cunha A, Sudhir A. Overcoming the challenges in diagnosis of AQP4-IgG positive neuromyelitis optica spectrum disorders in resource poor settings using an indigenized and cost effective cell based assay. J Neuroimmunol 2021;360:577706. [PMID: 34507014 DOI: 10.1016/j.jneuroim.2021.577706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Gudkova VV, Kimelfeld EI, Paderina VP, Koshurnikov DS, Ulianov DI, Ermakov DS, Maliutina NA. Opticoneuromyelitis associated with melanoma. Case report. Consilium Medicum 2021;23:884-90. [DOI: 10.26442/20751753.2021.11.201159] [Reference Citation Analysis]
7 Kini S, Bhat YR, Karegowda LH. Torticollis as an Initial Manifestation of a Seronegative Demyelinating Disorder in a Child: A Case Report. Journal of Pediatric Neurology. [DOI: 10.1055/s-0041-1736599] [Reference Citation Analysis]
8 Lin TY, Chien C, Lu A, Paul F, Zimmermann HG. Retinal optical coherence tomography and magnetic resonance imaging in neuromyelitis optica spectrum disorders and MOG-antibody associated disorders: an updated review. Expert Rev Neurother 2021;21:1101-23. [PMID: 34551653 DOI: 10.1080/14737175.2021.1982697] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Waliszewska-Prosół M, Chojdak-Łukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects. Int J Mol Sci 2021;22:2801. [PMID: 33802046 DOI: 10.3390/ijms22062801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
10 Collongues N, Alves Do Rego C, Bourre B, Biotti D, Marignier R, da Silva AM, Santos E, Maillart E, Papeix C, Palace J, Leite MIS, De Seze J. Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder. Neurology 2021;96:e2006-15. [PMID: 33627499 DOI: 10.1212/WNL.0000000000011744] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
11 Houen G, Trier NH, Frederiksen JL. Epstein-Barr Virus and Multiple Sclerosis. Front Immunol 2020;11:587078. [PMID: 33391262 DOI: 10.3389/fimmu.2020.587078] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
12 Gao Y, Zhang B, Yang J. Satralizumab for the Treatment of Neuromyelitis Optica Spectrum Disorders. Ann Pharmacother 2021;55:1167-71. [PMID: 33246373 DOI: 10.1177/1060028020976669] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Boziki M, Sintila SA, Ioannidis P, Grigoriadis N. Biomarkers in Rare Demyelinating Disease of the Central Nervous System. Int J Mol Sci 2020;21:E8409. [PMID: 33182495 DOI: 10.3390/ijms21218409] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Osswald D, De Seze J, Collongues N, Speeg-schatz C. Comparaison clinico-épidémiologique des pathologies du spectre des neuromyélites optiques. Journal Français d'Ophtalmologie 2020;43:598-603. [DOI: 10.1016/j.jfo.2019.11.011] [Reference Citation Analysis]
15 Server Alonso A, Sakinis T, Pfeiffer HCV, Sandvig I, Barlinn J, Marthinsen PB. Understanding Pediatric Neuroimmune Disorder Conflicts: A Neuroradiologic Approach in the Molecular Era. Radiographics 2020;40:1395-411. [PMID: 32735475 DOI: 10.1148/rg.2020200032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
16 Zhu W, Zhang Y, Wang Z, Fu Y, Yan Y. Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: From Bench to Bedside. Neurosci Bull 2020;36:1213-24. [PMID: 32533450 DOI: 10.1007/s12264-020-00525-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Hung SC. Imaging of Neuromyelitis Optica Spectrum Disorders. Semin Ultrasound CT MR 2020;41:319-31. [PMID: 32448488 DOI: 10.1053/j.sult.2020.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Rabasté S, Cobo-Calvo A, Nistiriuc-Muntean V, Vukusic S, Marignier R, Cotton F; OFSEP, NOMADMUS Study Group. Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy. J Neuroradiol 2021;48:28-36. [PMID: 32407908 DOI: 10.1016/j.neurad.2020.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
19 Ong ZM, Schee JP, Viswanathan S. Therapeutic Plasma Exchange in Neuromyelitis Optica Spectrum Disorders and Related Disorders in Resource‐Limited Settings: Outcomes in a Multiethnic Single‐Center Population. Ther Apher Dial 2020;24:312-23. [DOI: 10.1111/1744-9987.13446] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Collongues N, Ayme-Dietrich E, Monassier L, de Seze J. Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. Drugs 2019;79:125-42. [PMID: 30623348 DOI: 10.1007/s40265-018-1039-7] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 10.3] [Reference Citation Analysis]
21 Camacho J, Zuleta S, Alba MP, Hernandez A, Navas C. Neuromyelitis optica spectrum disorder in pediatrics. Case report. Case reports 2019;5:11-8. [DOI: 10.15446/cr.v5n1.74943] [Reference Citation Analysis]
22 Lambert J, Mejia S, Vojdani A. Plant and human aquaporins: pathogenesis from gut to brain. Immunol Res 2019;67:12-20. [DOI: 10.1007/s12026-018-9046-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]